Canadian Imperial Bank Of Commerce Stock Rises Friday, Still Underperforms Market
Dow Jones2026/08/21 20:32This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Canadian Imperial Bank of Commerce CM inched 0.34% higher to C$160.32 Friday, in what proved to be an all-around positive trading session for the Canadian market, with the S&P/TSX Composite Index rising 0.70% to 36,620.23.
Canadian Imperial Bank of Commerce closed 7.3% short of its 52-week high of C$172.87, which the company achieved on August 17th.
Trading volume of 1.7 M shares remained below its 50-day average volume of 2.5 M.
Data source: Dow Jones Market Data, FactSet. Data compiled August 21, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
August 21, 2026 16:32 ET (20:32 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The second wave of energy price increases is looming! European Central Bank’s Lane warns: eurozone inflation will be higher and more persistent
Philip Lane, Chief Economist of the European Central Bank, stated that a new round of high energy prices means inflation in the eurozone will remain elevated for longer than the ECB initially anticipated.
Bitcoin Trades Around $86K as FOMO Hits Highest Level Since 2024
siRNA rising star ADARx (ADRX.US) launches $350 millions IPO, AbbVie subscribes to 4.9% of shares with a maximum investment of $100 millions
ADARx plans to raise $350 millions and list on Nasdaq. AbbVie will invest up to $100 millions to acquire a 4.9% stake, with a median valuation of $1.8 billions.
Roche (RHHBY.US) weight loss injection shows positive mid-term trial results: average weight loss of 15.5% over 48 weeks, blood sugar levels drop by 2.65%.
The experimental weight-loss injection enicepatide simultaneously lowered blood sugar and body weight in overweight or obese patients with type 2 diabetes during a mid-stage clinical trial.
Crypto prices
More
